secwatch / observer
8-K filed June 16, 2026, 5:00 PM ET ticker SLN CIK 0001479615
other confidence high sentiment neutral materiality 0.10

All 9 resolutions pass at Silence Therapeutics 2026 AGM including director re-elections and say-on-pay

Silence Therapeutics plc

item 5.07

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Silence Therapeutics plc shareholders approved To approve the directors' remuneration report for the year ended December 31, 2025, which is set forth as Annex A to the Proxy Statement and on pages 32 to 54 (inclusive) of the 2025 U.K. Annual Report. at the 2026-06-16 meeting.

Proposal
say on pay
Outcome
passed
Meeting
2026-06-16
Exact text from the filing
Resolution 8 : To approve the directors' remuneration report for the year ended December 31, 2025, which is set forth as Annex A to the Proxy Statement and on pages 32 to 54 (inclusive) of the 2025 U.K. Annual Report. The votes were cast as follows: For Against Abstain 48,251,875 66,518 4,404,018
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Silence Therapeutics plc shareholders approved To receive and adopt the Company's U.K. statutory annual accounts and reports for the year ended December 31, 2025 (the “2025 U.K. Annual Report”). at the 2026-06-16 meeting.

Outcome
passed
Meeting
2026-06-16
Exact text from the filing
Resolution 7 : To receive and adopt the Company's U.K. statutory annual accounts and reports for the year ended December 31, 2025 (the “2025 U.K. Annual Report”). The votes were cast as follows: For Against Abstain 52,715,076 3,108 4,077
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Silence Therapeutics plc shareholders approved To approve the application of Article 159 of the Company's articles of association from the conclusion of this AGM to the conclusion of the next annual general meeting of the Company. at the 2026-06-16 meeting.

Outcome
passed
Meeting
2026-06-16
Exact text from the filing
Resolution 9 : To approve the application of Article 159 of the Company's articles of association from the conclusion of this AGM to the conclusion of the next annual general meeting of the Company. The votes were cast as follows: For Against Abstain 48,307,317 9,333 4,405,761
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Silence Therapeutics plc shareholders approved To authorize the Audit & Risk Committee to determine the U.K. statutory auditors' remuneration for the year ending December 31, 2026. at the 2026-06-16 meeting.

Outcome
passed
Meeting
2026-06-16
Exact text from the filing
Resolution 6 : To authorize the Audit & Risk Committee to determine the U.K. statutory auditors' remuneration for the year ending December 31, 2026. The votes were cast as follows: For Against Abstain 52,714,237 6,155 1,869
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Silence Therapeutics plc shareholders approved To re-appoint as a director of the Company Rhonda Hellums. at the 2026-06-16 meeting.

Proposal
director election
Outcome
passed
Meeting
2026-06-16
Exact text from the filing
Resolution 1 : To re-appoint as a director of the Company Rhonda Hellums. The votes were cast as follows: For Against Abstain 47,160,731 5,557,090 4,680
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Silence Therapeutics plc shareholders approved To ratify the appointment of PricewaterhouseCoopers LLP as the Company's U.S. independent registered public accounting firm for the year ending December 31, 2026. at the 2026-06-16 meeting.

Proposal
auditor ratification
Outcome
passed
Meeting
2026-06-16
Exact text from the filing
Resolution 4 : To ratify the appointment of PricewaterhouseCoopers LLP as the Company's U.S. independent registered public accounting firm for the year ending December 31, 2026. The votes were cast as follows: For Against Abstain 52,718,407 2,885 1,119
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Silence Therapeutics plc shareholders approved To re-appoint as a director of the Company James Ede-Golightly. at the 2026-06-16 meeting.

Proposal
director election
Outcome
passed
Meeting
2026-06-16
Exact text from the filing
Resolution 2 : To re-appoint as a director of the Company James Ede-Golightly. The votes were cast as follows: For Against Abstain 52,112,045 605,683 4,680
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Silence Therapeutics plc shareholders approved To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the Proxy Statement. at the 2026-06-16 meeting.

Proposal
say on pay
Outcome
passed
Meeting
2026-06-16
Exact text from the filing
Resolution 3 : To approve, on an advisory basis, the compensation of the Company's named executive officers, as disclosed in the Proxy Statement. The votes were cast as follows: For Against Abstain 48,234,208 73,667 4,414,536
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Silence Therapeutics plc shareholders approved To re-appoint PricewaterhouseCoopers LLP as the Company's U.K. statutory auditors, to hold office until the conclusion of the next annual general meeting of shareholders. at the 2026-06-16 meeting.

Proposal
auditor ratification
Outcome
passed
Meeting
2026-06-16
Exact text from the filing
Resolution 5 : To re-appoint PricewaterhouseCoopers LLP as the Company's U.K. statutory auditors, to hold office until the conclusion of the next annual general meeting of shareholders. The votes were cast as follows: For Against Abstain 52,718,407 2,885 1,119
View on SEC.gov

1639 shareholder votes filed in the last 30 days. Browse all shareholder votes →

Silence Therapeutics plc filing history →

Source: SEC EDGAR
accession 0001193125-26-272814
view filing index on sec.gov
view primary document
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.